Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Forecast Report Coverage

Expert Market Research's “Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of recurrent or metastatic HER2‑overexpressing solid tumors. It projects the future incidence and prevalence rates of recurrent or metastatic HER2‑overexpressing solid tumors cases across various populations. The study covers age, gender, and type as major determinants of the recurrent or metastatic HER2‑overexpressing solid tumors population. The report highlights patterns in the prevalence of recurrent or metastatic HER2‑overexpressing solid tumors over time and projects future trends based on multiple variables.

Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Understanding: Disease Overview

Recurrent or metastatic HER2-overexpressing solid tumors represent advanced malignancies characterized by amplification or overexpression of the HER2 receptor, driving aggressive tumor growth and poor prognosis. HER2 positivity is most established in breast cancer and gastric cancer, but it is also identified in subsets of lung, colorectal, endometrial, and salivary gland cancers. Recurrence refers to the disease returning after prior treatment, while metastatic disease indicates distant spread. HER2 overexpression promotes uncontrolled proliferation through activation of downstream signaling pathways, making HER2 a validated predictive biomarker and therapeutic target across tumor types.

Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Perspective

The recurrent or metastatic HER2‑overexpressing solid tumors epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for recurrent or metastatic HER2‑overexpressing solid tumors epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for recurrent or metastatic HER2‑overexpressing solid tumors and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization, in 2022, breast cancer was the most common cancer among women worldwide, with approximately 2.3 million new cases diagnosed and about 670,000 deaths reported globally that year.
• Approximately 15-20% of invasive breast cancer cases demonstrate HER2 overexpression or ERBB2 gene amplification, defining a distinct molecular subtype associated with more aggressive clinical behavior and targeted therapeutic eligibility.
• Approximately 15-24% of patients with localized HER2-positive breast cancer eventually experience metastatic recurrence following curative therapy, whereas 3-10% are diagnosed with metastatic disease at initial presentation (de novo metastatic disease).
• Breast cancer generally increases with age, with the highest overall new case percentages in women aged 55-74 years, but this pattern applies to all subtypes combined.
• >99% of HER2-overexpressing breast cancer cases are female, with male incidence being extremely low (<1%).

Read more about this report - Request a Free Sample

Country-wise Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology

The recurrent or metastatic HER2‑overexpressing solid tumors epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, recurrent or metastatic Breast Cancer represents a clinically significant disease burden. Approximately 168,000 women were living with metastatic breast cancer in 2020. HER2-positive disease accounts for about 20% of all breast cancer cases, reflecting a substantial molecular subgroup within advanced disease populations. According to the Surveillance, Epidemiology, and End Results Program (SEER 2018-2022), 9% of newly diagnosed female breast cancer cases are classified as HR-positive/HER2-positive. Collectively, these data underscore the measurable presence of HER2-overexpressing tumors within the recurrent and metastatic breast cancer landscape in the United States.

Recurrent or Metastatic HER2‑Overexpressing Solid Tumors: Treatment Overview

Treatment focuses on HER2-targeted therapy combined with systemic anticancer approaches. Standard regimens include monoclonal antibodies such as trastuzumab and pertuzumab, antibody-drug conjugates like trastuzumab deruxtecan, and tyrosine kinase inhibitors including Tucatinib. Treatment selection depends on tumor type, prior therapy, performance status, and extent of metastasis. Chemotherapy and immunotherapy may be incorporated depending on histology. Sequential HER2 blockade is common in relapsed settings, with therapy continued until progression or unacceptable toxicity occurs.

Key Questions Answered

• What are the key findings of recurrent or metastatic HER2‑overexpressing solid tumors epidemiology in the 8 major markets?
• What will be the total number of patients with recurrent or metastatic HER2‑overexpressing solid tumors across the 8 major markets during the forecast period?
• What was the country-wise recurrent or metastatic HER2‑overexpressing solid tumors epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of recurrent or metastatic HER2‑overexpressing solid tumors patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of recurrent or metastatic HER2‑overexpressing solid tumors during the forecast period of 2026-2035?
• What are the currently available treatments for recurrent or metastatic HER2‑overexpressing solid tumors?
• What are the disease risks, signs, symptoms, and unmet needs of recurrent or metastatic HER2‑overexpressing solid tumors?

Scope of the Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of recurrent or metastatic HER2‑overexpressing solid tumors based on several factors.
• Recurrent or Metastatic HER2‑Overexpressing Solid Tumors Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The recurrent or metastatic HER2‑overexpressing solid tumors report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

HER2 Positive Breast Cancer Pipeline Analysis

HER2 Positive Gastric Cancer Epidemiology